Sitryx
Harnessing immune cell metabolism to develop oral therapies for autoimmune disorders
The immune system runs on cellular metabolism, but when that balance breaks down, it can drive chronic inflammatory disease.
Sitryx targets metabolic pathways within immune cells to rebalance the immune system – not just suppress it – to resolve chronic autoimmune and inflammatory diseases.
Founded by six world-leading researchers in immunometabolism, and backed by a major collaboration with Eli Lilly, the company is advancing five new treatments for autoimmune and inflammatory conditions.
Sector
Life Sciences
Stage
- Series A